Perspectives and Insights From PV Experts
The resources on this page offer information and insights about Jakafi® (ruxolitinib) and treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea (HU). Be sure to check back regularly as new materials will be added as they become available.
Dr Mesa’s Perspective: Controlling Hct and Assessing Symptoms in Patients With Polycythemia Vera (PV)

Dr Mesa’s Perspective:
Controlling Hct and Assessing
Symptoms in Patients With
Polycythemia Vera
Hematologist-oncologist Dr Ruben Mesa discusses the importance of targeting optimal blood counts, assessing disease-related symptoms, and understanding when it may be the right time to intervene with Jakafi.

Dr Kuykendall's Perspective: Hct Control and WBC Reduction in Patients With PV
Dr Kuykendall's Perspective:
Hct Control and WBC Reduction in Patients With PV
Hematologist-oncologist Dr Andrew Kuykendall shares how he manages progressive white blood cell (WBC) counts and when it may be time to intervene with Jakafi.

Dr Kuykendall's Perspective: Controlling Hct and Assessing Symptoms in Patients With PV
Dr Kuykendall's Perspective:
Controlling Hct and Assessing Symptoms in Patients With PV
Hematologist-oncologist Dr Andrew Kuykendall details how he uncovers symptoms in patients with PV, and when it may be time to intervene with Jakafi.

Mechanism of Action of Jakafi
Mechanism of Action of Jakafi
Hematology specialist Dr Harry Erba reviews the mechanism of action of Jakafi, a JAK1 and JAK2 inhibitor, highlighting how Jakafi works to inhibit overactive JAK pathway signaling. Dr Erba also discusses... Read More

Dosing of Jakafi in Patients With PV Who Have Had an Inadequate Response to or Are Intolerant of HU
Dosing of Jakafi in Patients With PV Who Have Had an Inadequate Response to or Are Intolerant of HU
Hematology specialist Dr Harry Erba discusses the appropriate dosing of Jakafi in patients with... Read More